Chris Godwin

Godwin didn't make his season debut until Week 4 while completing his recovery from a 2024 ankle injury, and after posting matching three-catch efforts in his first two games, he went on to log five consecutive absences due to a fibula injury. This pattern of recurring lower-body injuries (ACL 2021, ankle 2024, fibula 2025) significantly impacts durability and upside.

Emeka Egbuka (dynasty value vs. Godwin's) has effectively supplanted Godwin as the team's WR1, as confirmed by the market. Godwin's W18 target share of just 5% underscores his reduced role even when healthy, with the trend clearly pointing downward.

Godwin carries a $33.7 million cap hit in 2026, with multiple reports indicating the Buccaneers are exploring trades or restructures. The team may move on from him this offseason to create cap space and prioritize younger receivers like Egbuka and McMillan.

Godwin is seemingly Baker Mayfield's top target. The two have strong on-field chemistry, and Mayfield's continuation as QB ensures continued target opportunities when healthy.

In his seven games, the veteran receiver averaged 19.7 fantasy PPG and caught 79% of his passes, both of which ranked second at the position. Godwin scored five TDs in seven games. If fully healthy for a full season, he can still produce at elite WR1-2 level.

Mike Evans' departure to the San Francisco 49ers opens up a significant volume of targets in Tampa Bay's passing offense. Godwin is the most experienced option to absorb a portion of those looks alongside Egbuka, and his veteran rapport with Mayfield gives him an edge for high-leverage situations.

When healthy in 2025, Godwin averaged 19.7 fantasy PPG with 5 TDs in 7 games, demonstrating elite per-game production and maintained chemistry with Baker Mayfield. A full healthy season could yield WR2 upside.

Godwin's dynasty value has cratered to tier 6 after his disastrous 2025 season. If he stays in Tampa and returns to health, there's significant upside for contending teams willing to bet on a bounce-back at depressed cost.